AstraZeneca's IMFINZI Secures FDA Nod for Bladder Cancer Combination Therapy

Event summary

  • AstraZeneca's IMFINZI (durvalumab) in combination with BCG therapy approved by the FDA for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC).
  • Approval based on positive results from the POTOMAC Phase III trial, presented at ESMO Congress 2025 and published in The Lancet.
  • The combination therapy demonstrated a 32% reduction in the risk of disease recurrence, progression, or death compared to BCG alone.
  • IMFINZI is the first immunotherapy combination regimen approved for this indication in over 30 years.
  • Regulatory submissions based on the POTOMAC results are under review in the European Union, Japan, and several other countries.

The big picture

This approval marks a significant milestone in the treatment of high-risk non-muscle-invasive bladder cancer, addressing a critical unmet need in a curative-intent setting. The success of the IMFINZI-BCG combination therapy underscores the growing role of immunotherapy in early-stage cancer treatment, potentially reshaping the standard of care. AstraZeneca's strategic focus on immuno-oncology continues to drive innovation, with IMFINZI playing a pivotal role in its portfolio.

What we're watching

Regulatory Momentum
Whether the FDA approval will accelerate regulatory reviews in the EU, Japan, and other countries, expanding market access for IMFINZI.
Clinical Impact
The pace at which the IMFINZI-BCG combination therapy will be adopted in clinical practice and its potential to become the new standard of care for high-risk NMIBC.
Competitive Dynamics
How this approval positions AstraZeneca against competitors in the bladder cancer treatment landscape, particularly in the immunotherapy space.

Related topics

Oncology